December 13, 2024 12:40 PM EST

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

Katherine Lewin

News Reporter

The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday but said a label expansion of Eli Lilly’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

Katherine Lewin

News Reporter

Sign up to read this article for free.

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Gilead names Dietmar Berger CMO as it eyes R&D reset

Boundless shares dip as it nixes cancer asset, reshuffles execs

The key to faster, more impactful research? Put patients in the driver’s seat

EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary

Katherine Lewin

News Reporter

Sign up to read this article for free.

Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M

Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses

Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron

Gilead names Di­et­mar Berg­er CMO as it eyes R&D re­set

Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

EMA's committee says expanded label for Lilly's Mounjaro into sleep apnea not necessary

AbbVie makes another small I&I acquisition, buying Nimble for $200M

Bicycle Therapeutics stock sinks following release of topline data, post-hoc analyses

Xaira hires former Roche exec as CMO; 'Tis the season for retirements at Alnylam, Regeneron

Gilead names Dietmar Berger CMO as it eyes R&D reset

Boundless shares dip as it nixes cancer asset, reshuffles execs

The key to faster, more impactful research? Put patients in the driver’s seat